contributes to the mounting evidence that ALK is an immunogenic oncoprotein and bolsters the argument that an ALK cancer vaccine is needed to prime the immune system for effective immunotherapy in ALK+ NSCLC patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.